Mckesson Corp MCK
We take great care to ensure that the data presented and summarized in this overview for MCKESSON CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MCK
View all-
Vanguard Group Inc Valley Forge, PA11.9MShares$8.47 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY11.5MShares$8.18 Billion0.15% of portfolio
-
State Street Corp Boston, MA5.71MShares$4.07 Billion0.13% of portfolio
-
Massachusetts Financial Services CO Boston, MA4.72MShares$3.36 Billion0.9% of portfolio
-
Jpmorgan Chase & CO New York, NY4.35MShares$3.1 Billion0.2% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.85MShares$2.03 Billion1.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.66MShares$1.9 Billion0.12% of portfolio
-
Franklin Resources Inc San Mateo, CA2.62MShares$1.87 Billion0.44% of portfolio
-
Morgan Stanley New York, NY2.4MShares$1.71 Billion0.1% of portfolio
-
Gamma Investing LLC Foster City, CA2.39MShares$1.71 Billion0.02% of portfolio
Latest Institutional Activity in MCK
Top Purchases
Top Sells
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Insider Transactions at MCK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 06
2025
|
Brian S. Tyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,962
-17.33%
|
$5,681,908
$634.24 P/Share
|
|
Mar 01
2025
|
Napoleon B Rutledge Jr SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
243
-4.79%
|
$155,520
$640.26 P/Share
|
|
Mar 01
2025
|
Napoleon B Rutledge Jr SVP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
786
+12.98%
|
-
|
|
Feb 28
2025
|
Brian S. Tyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,961
-14.77%
|
$5,591,664
$624.0 P/Share
|
|
Feb 25
2025
|
Michele Lau EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
312
-10.0%
|
$188,760
$605.0 P/Share
|
|
Feb 21
2025
|
Brian S. Tyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,961
-12.87%
|
$5,349,717
$597.99 P/Share
|
|
Feb 14
2025
|
Brian S. Tyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,961
-11.4%
|
$5,376,600
$600.66 P/Share
|
|
Feb 12
2025
|
Le Ann B Smith EVP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
188
-15.17%
|
$114,492
$609.59 P/Share
|
|
Feb 10
2025
|
Le Ann B Smith EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
132
-9.63%
|
$79,596
$603.4 P/Share
|
|
Feb 10
2025
|
Le Ann B Smith EVP & Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
507
+27.0%
|
-
|
|
Feb 09
2025
|
Michele Lau EVP and Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,627
-34.65%
|
$968,065
$595.69 P/Share
|
|
Feb 09
2025
|
Michele Lau EVP and Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,747
+48.64%
|
-
|
|
Jan 02
2025
|
Le Ann B Smith EVP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
579
-40.12%
|
$331,188
$572.79 P/Share
|
|
Dec 09
2024
|
Le Ann B Smith EVP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
579
-28.64%
|
$348,558
$602.81 P/Share
|
|
Sep 05
2024
|
Brian S. Tyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,753
-4.56%
|
$2,105,433
$561.1 P/Share
|
|
Aug 05
2024
|
Brian S. Tyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,753
-4.36%
|
$2,349,378
$626.03 P/Share
|
|
Jul 31
2024
|
Maria Martinez Director |
BUY
Grant, award, or other acquisition
|
Direct |
349
+50.0%
|
-
|
|
Jul 31
2024
|
Dominic J Caruso Director |
BUY
Grant, award, or other acquisition
|
Direct |
349
+50.0%
|
-
|
|
Jul 03
2024
|
Brian S. Tyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,753
-4.18%
|
$2,176,740
$580.92 P/Share
|
|
Jun 11
2024
|
Le Ann B Smith EVP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
600
-22.88%
|
$351,000
$585.53 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 104K shares |
|---|---|
| Exercise of conversion of derivative security | 33.2K shares |
| Open market or private sale | 77.5K shares |
|---|---|
| Payment of exercise price or tax liability | 53.7K shares |
| Bona fide gift | 3.6K shares |